Russell Investments Group Ltd. boosted its position in shares of Novartis AG (NYSE:NVS – Free Report) by 148.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 136,987 shares of the company’s stock after acquiring an additional 81,954 shares during the period. Russell Investments Group Ltd.’s holdings in Novartis were worth $19,530,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of NVS. Highland Investment Advisors LLC acquired a new stake in shares of Novartis in the 2nd quarter worth $25,000. Evolution Wealth Management Inc. lifted its position in Novartis by 552.0% in the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after purchasing an additional 138 shares during the period. Atlatl Advisers LLC acquired a new stake in Novartis in the second quarter valued at about $26,000. Curry Webb Wealth Management LLC acquired a new stake in Novartis in the third quarter valued at about $28,000. Finally, Silicon Valley Capital Partners boosted its holdings in Novartis by 519.4% in the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock valued at $30,000 after purchasing an additional 161 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.
Novartis Price Performance
NVS opened at $155.20 on Thursday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.70 and a current ratio of 0.88. The company has a market capitalization of $296.15 billion, a P/E ratio of 17.90, a PEG ratio of 2.91 and a beta of 0.40. Novartis AG has a 1-year low of $123.24 and a 1-year high of $170.46. The company has a 50-day moving average of $149.91 and a 200-day moving average of $152.74.
Analysts Set New Price Targets
Several equities analysts recently weighed in on NVS shares. Weiss Ratings downgraded Novartis from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. Berenberg Bank decreased their target price on Novartis from $147.00 to $130.00 and set a “hold” rating on the stock in a research report on Friday, September 11th. DZ Bank assumed coverage on Novartis in a research report on Wednesday, October 28th. They set a “hold” rating on the stock. Sanford C. Bernstein reaffirmed a “neutral” rating on shares of Novartis in a research note on Wednesday, July 22nd. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a research report on Wednesday, October 28th. Six research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Novartis has a consensus rating of “Hold” and a consensus target price of $152.25.
View Our Latest Research Report on NVS
Novartis Company Profile
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Further Reading
- Five stocks we like better than Novartis
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
